Myriad Genetics Inc

MYGN:NASDAQ
RT Quote | NASDAQ | USD
Last | 01/26/21 EST
26.23quote price arrow down-0.32 (-1.21%)
Volume
380,701
52 week range
9.24 - 30.13

...

Loading . . .

KEY STATS

  • Open26.90
  • Day High26.90
  • Day Low26.06
  • Prev Close26.23
  • 52 Week High30.13
  • 52 Week High Date02/05/20
  • 52 Week Low9.24
  • 52 Week Low Date03/18/20
  • Market Cap1,972.76M
  • Shares Out75.21M
  • 10 Day Average Volume0.89M
  • Dividend-
  • Dividend Yield-
  • Beta1.76
  • 1 Year % Change-8.35

RATIOS/PROFITABILITY

  • EPS (TTM)-2.87
  • P/E (TTM)-9.13
  • Fwd P/E (NTM)-126.71
  • EBITDA (MRQ)-80.50M
  • ROE (MRQ)-21.58%
  • Revenue (MRQ)597.50M
  • Gross Margin (MRQ)69.77%
  • Net Margin (MRQ)-35.85%
  • Debt To Equity (MRQ)24.70%

EVENTS

  • Earnings Date02/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest MYGN News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a...
S. Louise Phanstiel CPA
Chairman
Paul Diaz J.D.
President
R. Bryan Riggsbee CPA
Chief Financial Officer
Paul Parkinson
Executive Vice President
Benjamin Jackson J.D.
Executive Vice President
Address
320 S Wakara Way
Salt Lake City, UT
84108-1214
United States